We are delighted to welcome ReBio Pharma to the La Tulipe community, further enriching our dynamic ecosystem of biotech innovators dedicated to addressing urgent medical needs.
ReBio Pharma is a biotechnology company focused on advancing innovative therapies for severe ocular diseases, particularly in areas with significant unmet medical needs. Combining deep scientific expertise with a translational vision, the company aims to bring new solutions closer to patients.
As part of its growth at La Tulipe, ReBio Pharma has refined its strategic focus on ocular oncology, concentrating efforts on its lead program RBP-01, a novel targeted therapy for uveal melanoma, the most common primary eye cancer in adults — a disease with limited treatment options and no approved medical therapy.
The company’s latest announcement confirms that **RBP-01 is expected to enter clinical trials in Q1 2026, representing an important milestone toward translating its preclinical research into potential patient-benefitting therapies. This progress is supported by collaborations with world-leading ocular oncology experts and recent preclinical results that have been selected for an upcoming oral presentation at a major scientific conference.
ReBio Pharma harnesses its proprietary SiSu® therapeutic amplifier technology — designed to deliver potent, localized drug exposure with minimal off-target toxicity — to improve cancer control while preserving vision.
🔍 Explore more about ReBio Pharma at La Tulipe:
👉 https://www.tulipe-frm.ch/start-up/rebio-pharma
🔍 Discover their latest news and pipeline developments:
👉 www.rebiopharma.com
👉 https://www.rebiopharma.com/news/rebio-pharma-relaunches-with-strategic-focus-on-ocular-oncology-as-lead-program-nears-the-clinic
We look forward to following ReBio Pharma’s journey as it advances innovative, vision-preserving therapies for patients with high unmet medical need, and we are proud to host them within La Tulipe’s vibrant ecosystem.
#LaTulipe #Biotech #OcularOncology #Innovation #TranslationalResearch #GenevaEcosystem
